Logo image of AKRO

AKERO THERAPEUTICS INC (AKRO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:AKRO - US00973Y1082 - Common Stock

54.36 USD
+0.01 (+0.02%)
Last: 11/28/2025, 8:12:20 PM
54.36 USD
0 (0%)
After Hours: 11/28/2025, 8:12:20 PM
Fundamental Rating

3

Taking everything into account, AKRO scores 3 out of 10 in our fundamental rating. AKRO was compared to 533 industry peers in the Biotechnology industry. While AKRO has a great health rating, there are worries on its profitability. AKRO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AKRO has reported negative net income.
In the past year AKRO has reported a negative cash flow from operations.
In the past 5 years AKRO always reported negative net income.
AKRO had a negative operating cash flow in each of the past 5 years.
AKRO Yearly Net Income VS EBIT VS OCF VS FCFAKRO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

With a decent Return On Assets value of -29.12%, AKRO is doing good in the industry, outperforming 68.11% of the companies in the same industry.
The Return On Equity of AKRO (-30.58%) is better than 77.11% of its industry peers.
Industry RankSector Rank
ROA -29.12%
ROE -30.58%
ROIC N/A
ROA(3y)-29.36%
ROA(5y)-33.72%
ROE(3y)-32.08%
ROE(5y)-37.29%
ROIC(3y)N/A
ROIC(5y)N/A
AKRO Yearly ROA, ROE, ROICAKRO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AKRO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AKRO Yearly Profit, Operating, Gross MarginsAKRO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, AKRO has more shares outstanding
The number of shares outstanding for AKRO has been increased compared to 5 years ago.
AKRO has a better debt/assets ratio than last year.
AKRO Yearly Shares OutstandingAKRO Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
AKRO Yearly Total Debt VS Total AssetsAKRO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 52.83 indicates that AKRO is not in any danger for bankruptcy at the moment.
AKRO's Altman-Z score of 52.83 is amongst the best of the industry. AKRO outperforms 96.81% of its industry peers.
AKRO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 52.83
ROIC/WACCN/A
WACCN/A
AKRO Yearly LT Debt VS Equity VS FCFAKRO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

A Current Ratio of 15.83 indicates that AKRO has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 15.83, AKRO belongs to the top of the industry, outperforming 92.68% of the companies in the same industry.
A Quick Ratio of 15.83 indicates that AKRO has no problem at all paying its short term obligations.
AKRO's Quick ratio of 15.83 is amongst the best of the industry. AKRO outperforms 92.68% of its industry peers.
Industry RankSector Rank
Current Ratio 15.83
Quick Ratio 15.83
AKRO Yearly Current Assets VS Current LiabilitesAKRO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

1

3. Growth

3.1 Past

AKRO shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 0.53%.
EPS 1Y (TTM)0.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

AKRO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.74% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y0.88%
EPS Next 2Y-5.84%
EPS Next 3Y-6.92%
EPS Next 5Y20.74%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AKRO Yearly Revenue VS EstimatesAKRO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
AKRO Yearly EPS VS EstimatesAKRO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AKRO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AKRO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AKRO Price Earnings VS Forward Price EarningsAKRO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AKRO Per share dataAKRO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

A cheap valuation may be justified as AKRO's earnings are expected to decrease with -6.92% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.84%
EPS Next 3Y-6.92%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AKRO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AKERO THERAPEUTICS INC

NASDAQ:AKRO (11/28/2025, 8:12:20 PM)

After market: 54.36 0 (0%)

54.36

+0.01 (+0.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2025-11-07/amc
Earnings (Next)02-26 2026-02-26/amc
Inst Owners106.92%
Inst Owner Change-3.79%
Ins Owners1.24%
Ins Owner Change-0.95%
Market Cap4.47B
Revenue(TTM)N/A
Net Income(TTM)-292.82M
Analysts73.75
Price Target64.26 (18.21%)
Short Float %6.16%
Short Ratio1.77
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.5%
Min EPS beat(2)-4.15%
Max EPS beat(2)7.14%
EPS beat(4)3
Avg EPS beat(4)6.96%
Min EPS beat(4)-4.15%
Max EPS beat(4)15.77%
EPS beat(8)5
Avg EPS beat(8)2.53%
EPS beat(12)8
Avg EPS beat(12)7%
EPS beat(16)10
Avg EPS beat(16)4.45%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-15.18%
PT rev (3m)-18.09%
EPS NQ rev (1m)-3.02%
EPS NQ rev (3m)2.13%
EPS NY rev (1m)0%
EPS NY rev (3m)2.4%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.55
P/tB 4.55
EV/EBITDA N/A
EPS(TTM)-3.73
EYN/A
EPS(NY)-4.2
Fwd EYN/A
FCF(TTM)-3.12
FCFYN/A
OCF(TTM)-3.12
OCFYN/A
SpS0
BVpS11.95
TBVpS11.95
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -29.12%
ROE -30.58%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-29.36%
ROA(5y)-33.72%
ROE(3y)-32.08%
ROE(5y)-37.29%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.83
Quick Ratio 15.83
Altman-Z 52.83
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.67%
EPS Next Y0.88%
EPS Next 2Y-5.84%
EPS Next 3Y-6.92%
EPS Next 5Y20.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-22.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.39%
EBIT Next 3Y-18.12%
EBIT Next 5YN/A
FCF growth 1Y-104.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-104.64%
OCF growth 3YN/A
OCF growth 5YN/A

AKERO THERAPEUTICS INC / AKRO FAQ

Can you provide the ChartMill fundamental rating for AKERO THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to AKRO.


What is the valuation status for AKRO stock?

ChartMill assigns a valuation rating of 0 / 10 to AKERO THERAPEUTICS INC (AKRO). This can be considered as Overvalued.


How profitable is AKERO THERAPEUTICS INC (AKRO) stock?

AKERO THERAPEUTICS INC (AKRO) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for AKRO stock?

The Earnings per Share (EPS) of AKERO THERAPEUTICS INC (AKRO) is expected to grow by 0.88% in the next year.